NCT01542437View on ClinicalTrials.gov

Treatment With BIBW 2992, Irreversible Inhibitor of EGFR and HER-2 in Non-small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2017

Conditions
Non-Small Cell Lung CancerEGFRHER-2
Interventions
DRUG

BIBW 2992

"All patients will receive: BIBW 2992 40mg every 24 hours orally, where a cycle corresponds to complete this treatment for 28 days; option 30mg/day dose reductions, according to established criteria.~Not to be compared with any other drug."

Trial Locations (1)

14080

National Cancer Institute of Mexico, Mexico City

All Listed Sponsors
lead

Instituto Nacional de Cancerologia de Mexico

OTHER

NCT01542437 - Treatment With BIBW 2992, Irreversible Inhibitor of EGFR and HER-2 in Non-small Cell Lung Cancer | Biotech Hunter | Biotech Hunter